Vilin Bio Med Ltd

As of 24-Oct, Vilin Bio Med Ltd's stock price is at 26.50, down 1.85%, and has underperformed its sector. Despite a 3.72% gain over the past month, recent declines and reduced investor participation indicate it is lagging behind broader market trends.

As of 17-Oct, Vilin Bio Med Ltd's stock price is at 27.95, reflecting a 4.29% gain and strong performance compared to its sector and the broader market. Despite a decline in investor participation, the stock has shown significant year-to-date growth of 27.05%.

As of 24-Sep, Vilin Bio Med Ltd's stock price is at 25.55, with a recent increase of 0.2%. The stock has shown strong performance, outperforming the sector and the benchmark Sensex year-to-date, indicating strong investor confidence despite broader market challenges.

As of September 23, 2025, Vilin Bio Med is considered very expensive with a PE ratio of 35.50, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex with a 41.27% return over the past year.

As of 23-Sep, Vilin Bio Med Ltd's stock price is at 25.50, down 2.86%, and has underperformed its sector today. Despite a recent decline, it has outperformed the benchmark year-to-date with a return of 15.91%.

As of September 22, 2025, Vilin Bio Med is considered overvalued with a valuation grade of expensive, reflected in its PE Ratio of 33.55 and EV to EBIT of 36.07, despite a strong 45.43% stock return over the past year.

As of 22-Sep, Vilin Bio Med Ltd's stock price is rising to 26.25, reflecting a 4.79% increase. Despite strong performance with significant gains year-to-date and over the past year, a decline in investor participation raises concerns for future trading activity.

As of 19-Sep, Vilin Bio Med Ltd's stock price is at 25.05, unchanged, with a year-to-date gain of 13.86% and a one-year increase of 38.78%. Despite recent positive performance, a decline in delivery volume and underperformance today may indicate cautious investor sentiment.

As of September 18, 2025, Vilin Bio Med is considered very expensive with a PE ratio of 34.94 and an EV to EBITDA of 37.46, indicating overvaluation compared to peers like Sun Pharma and Cipla, despite a strong 1-year return of 38.78%.

As of 18-Sep, Vilin Bio Med Ltd's stock price is at 25.05, unchanged, and has underperformed its sector by 1.05%. Despite a strong year-to-date increase of 13.86%, recent volatility and reduced investor participation have led to a 6.53% decline over the past month.

As of September 17, 2025, Vilin Bio Med is considered overvalued with a PE ratio of 34.94 and an EV to EBITDA of 37.46, indicating a premium compared to peers like Sun Pharma and Cipla, despite a strong one-year return of 33.6%.

As of 17-Sep, Vilin Bio Med Ltd's stock price is at 25.05, down 2.91%, and has underperformed its sector today. Despite a strong year-to-date gain of 13.86%, recent short-term declines indicate potential investor concerns.

As of September 16, 2025, Vilin Bio Med is considered very expensive and overvalued, with a PE Ratio of 35.99 and an EV to EBIT of 38.51, significantly higher than peers like Sun Pharma and Cipla, despite recent stock performance outpacing the Sensex.

As of 16-Sep, Vilin Bio Med Ltd's stock price is flat at 25.80, with a recent strong performance of 10.02% over the past week, but it has underperformed its sector today. Despite a year-to-date increase of 17.27% and a 42.54% rise over the past year, recent flat movement and short-term challenges are noted.

As of September 15, 2025, Vilin Bio Med is considered overvalued with a PE ratio of 32.64 and an EV to EBITDA ratio of 35.16, significantly higher than peers like Cipla and Dr. Reddy's Labs, despite a strong 1-year return of 42.54%.

As of 15-Sep, Vilin Bio Med Ltd's stock price is at 25.80, up 4.88%, and has outperformed its sector. Despite a recent decline in investor participation and mixed short-term performance, the stock has shown strong year-to-date gains compared to the Sensex.

As of 12-Sep, Vilin Bio Med Ltd's stock price is at 24.60, up 4.9% today but down 8.21% over the past month. Despite recent volatility and a significant drop in investor participation, the stock has shown strong long-term performance with a 34.43% increase over the past year.

As of 11-Sep, Vilin Bio Med Ltd is priced at 23.45 with no change, underperforming its sector by 0.47% and trading below all key moving averages. The stock has declined 4.87% over the past week and 12.99% over the past month, indicating a challenging performance period despite a year-to-date gain of 6.59%.

As of 10-Sep, Vilin Bio Med Ltd is priced at 23.45 with no change, underperforming its sector and showing declines over the past week and month, despite a year-to-date increase. The stock's recent performance diverges from the broader market trend, leading to investor caution.